Form 4: Shattuck Labs CFO Acquires 214,000 Stock Options

Andrew R. Neill, CFO of Shattuck Labs, Inc., was granted options to purchase 214,000 shares of the company's common stock on January 28, 2025.

Summary

• On January 28, 2025, Andrew R. Neill, the Chief Financial Officer of Shattuck Labs, Inc., acquired options to purchase 214,000 shares of the company's common stock.
• The exercise price of these options is $1.18 per share.
• The options vest over a four-year period, with 25% vesting on January 28, 2026, and the remaining 75% vesting in equal monthly installments through January 28, 2029, contingent upon Neill's continued service to the company.
• Following this transaction, Neill directly owns options for 214,000 shares of Shattuck Labs' common stock.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed neutrally to positively as it aligns management incentives with shareholder value. The sentiment is moderately positive due to the incentive alignment.

Positives

• The grant of stock options to the CFO aligns his interests with those of the shareholders, incentivizing him to work towards the company's success.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders by incentivizing them to increase the company's stock value.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the biotech industry.
• Companies like Amgen, Gilead, and Regeneron also use stock options to incentivize their executives.
• The vesting schedule and exercise price are generally in line with industry standards for similar-sized companies.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the CFO to improve company performance.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates